Lv1
40 积分 2023-11-13 加入
Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study
29天前
已完结
Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma
1个月前
已完结
Protein Posttranslational Modifications: The Chemistry of Proteome Diversifications
2个月前
已完结
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
3个月前
已完结
Tumor-Infiltrating Immunosuppressive Cells in Cancer-Cell Plasticity, Tumor Progression and Therapy Response
4个月前
已完结
Advancements in Bispecific Antibodies for Multiple Myeloma: What's New and What Lies Ahead
4个月前
已完结
Progression of disease within 6 months: revised early disease progression threshold for ENKTL
4个月前
已完结
Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial
4个月前
已完结
Quantification of circulating clonal plasma cells by multiparametric flow cytometry as a prognostic marker in patients with newly diagnosed multiple myeloma
6个月前
已完结
Detection of circulating normal and tumor plasma cells in newly diagnosed patients of multiple myeloma and their associations with clinical and laboratory parameters
6个月前
已完结
皖公网安备34019202002308
